Michael Jahn
University of Duisburg-Essen
28 Papers
82 Citations
Michael Jahn is an academic researcher from University of Duisburg-Essen. The author has contributed to research in topics: Medicine & Vaccination. The author has an hindex of 5, co-authored 28 publications. Previous affiliations of Michael Jahn include University Hospital Bonn.
Chat about Author
Papers
Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial
Alexander Zarbock,Mira Küllmar,Detlef Kindgen-Milles,Carola Wempe,Joachim Gerss,Timo Brandenburger,Thomas Dimski,Bartosz Tyczynski,Michael Jahn,Nils Mülling,Martin Mehrländer,Peter Rosenberger,Gernot Marx,Tim Philipp Simon,Ulrich Jaschinski,Philipp Deetjen,Christian Putensen,Jens-Christian Schewe,Stefan Kluge,Dominik Jarczak,Torsten Slowinski,Marc Bodenstein,Patrick Meybohm,Stefan Wirtz,Onnen Moerer,Andreas Kortgen,Philipp Simon,Sean M. Bagshaw,John A. Kellum,Melanie Meersch,Rich Investigators +30 more
TL;DR: Among critically ill patients with acute kidney injury receiving continuous kidney replacement therapy, anticoagulation with regional citrate, compared with systemic heparin anticoAGulation, resulted in significantly longer filter life span and 90-day mortality.
Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
Michael Jahn,Johannes Korth,Oliver Dorsch,Olympia E. Anastasiou,Burkhard Sorge-Hädicke,Bartosz Tyczynski,Anja Gäckler,Oliver Witzke,Ulf Dittmer,Sebastian Dolff,Benjamin Wilde,Andreas Kribben +11 more
TL;DR: In this article, the authors measured humoral immune responses in 72 hemodialysis patients after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech).
105
Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipients-A Single-Center Experience.
Jassin Rashidi-Alavijeh,A Frey,Moritz Passenberg,Johannes Korth,Jaqueline Zmudzinski,Olympia E. Anastasiou,Fuat H. Saner,Michael Jahn,Christian M. Lange,Katharina Willuweit +9 more
TL;DR: In this paper, the authors analyzed immunogenicity in 43 liver transplant recipients in a median of 15 days (IQR, 12-24) after receiving two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol, and compared these results to a control group consisting of 20 healthcare workers.
58
The predictive performance of SAPS 2 and SAPS 3 in an intermediate care unit for internal medicine at a German university transplant center; A retrospective analysis
TL;DR: In this study, the SAPS 3 exhibited high accuracy in prediction of mortality in ImCU patients with internal disorders particularly in patients with liver diseases and sepsis, while SAPS 2 showed a poor calibration-performance especially in Patients with low mortality risk.
COVID-19 vaccination in patients receiving dialysis.
TL;DR: In this paper, a personalized SARS-CoV-2 vaccination scheme was proposed for patients receiving dialysis, given the enhanced infection risks associated with dialysis and the fact that current vaccines do not replace nonpharmacological measures to prevent infection.